Rob Stein

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 25 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science and the Association of Health Care Journalists.

A tobacco product that its maker claims to be safer than cigarettes won qualified support from a Food and Drug Administration advisory panel Thursday.

The advisers voted 8-1 to support cigarette giant Philip Morris' claim that its "iQOS" system "significantly reduces your body's exposure to harmful or potentially harmful chemicals." The device heats tobacco but doesn't ignite it.

Chinese researchers have finally figured out how to clone a primate, using the same technique Scottish researchers devised to clone the first mammal, Dolly the sheep, in the mid-1990s.

The United States appears to be in the midst of an unusually severe flu season, officials at the federal Centers for Disease Control and Prevention said Friday.

The flu season started early, which is never a good sign, and the flu is already widespread throughout the country, the CDC's latest report shows. Half of states are reporting especially intense flu activity.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

RACHEL MARTIN, HOST:

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

SCOTT SIMON, HOST:

Scientists have now edited genes inside mice to prevent a form of inherited deafness.

While cautioning that much more research is needed, the scientists said they hope the technique might someday be used to prevent deafness in children born in families with a history of genetic hearing loss.

Before that could happen, however, extensive tests would be needed to determine whether the treatment is safe — and whether it would actually work in humans.

Updated at 4:17 p.m. ET to include comment from homeopathic pharmacists.

The Food and Drug Administration said it plans to crack down on the sale of some homeopathic products.

The agency unveiled a new, risk-based approach to regulating homeopathic treatments Monday that aims to protect the public from dangerous products.

Editor's note, Jan. 17: Some identifying information has been removed from this report to guard the privacy of the family that is part of the probiotics test.

It's a typical hectic morning at Michele's house in Northern Virginia when she gets a knock on her front door.

Health officials are warning that the United States may have an unusually harsh flu season this year.

But they stress that flu seasons are notoriously difficult to predict, and it's far too early to know for sure what may happen.

Eli Wheatley and Christian Guardino are among a growing number of patients whose lives are apparently being saved or radically improved by gene therapy.

Wheatley, 3, of Lebanon, Ky., and Guardino, 17, of Patchogue, N.Y., were both diagnosed with what were long thought to be incurable genetic disorders. In the past, Wheatley's condition would have probably killed him before his first birthday. Guardino's would have blinded him early in life.

But after receiving experimental gene therapies, both seem to be doing fine.

Pages